FDA OKs New Prophylactic Drug for Rare Hereditary Angioedema

Lanadelumab (Takhzyro) is the first monoclonal antibody to help prevent attacks of hereditary angioedema in patients age 12 years and older.
FDA Approvals

https://ift.tt/2LpEP61